ArticleThe World Allergy Organization journal2026
Androgenetic alopecia risk in allergic rhinitis: A cohort study of immune and antihistamine effects.
Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Androgenetic alopecia (AGA), though traditionally attributed to androgens and genetics, is increasingly linked to immune and inflammatory pathways. Allergic rhinitis (AR) and AGA may share overlapping mechanisms, including prostaglandin signaling abnormalities. Second-generation H1-antihistamines (sgSH), used to treat AR, have anti-inflammatory and immunomodulatory properties and may influence hair follicle biology. This study aimed to determine the association between AR and the risk of AGA and to explore whether the use of sgSH impacts this risk. Methods: This retrospective cohort study used the Taiwan National Health Insurance Research Database (NHIRD) between 2000 and 2021. Totally, 539,397 patients diagnosed with AR were included and categorized into sgSH users and nonusers. AGA incidence was estimated using Cox proportional hazards models. Results: AR patients had a higher risk of AGA (adjusted hazard ratio [aHR]: 1.81, 95% confidence interval [CI]: 1.69-1.93, p < 0.001). Among AR patients, sgSHs users had a lower risk of AGA than nonusers (aHR: 0.23, 95% CI: 0.20-0.26), with a dose-dependent effect ( Conclusions: This study observed that AR is associated with an increased risk of AGA and that sgSH use was statistically associated with a lower incidence of AGA, especially in younger individuals. However, the possibility that the observed associations reflect unmeasured confounding, rather than direct biological effects, cannot be ruled out. Future research should further clarify the complex relationship between allergic diseases and hair loss from multiple perspectives and assess the possibility of sgSH as a supplementary measure in the prevention or treatment of AGA. From a clinical perspective, our findings underscore the importance of heightened awareness of early hair loss in patients with chronic AR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.